Korro Bio operates as a clinical-stage genetic medicine company specializing in the discovery and development of novel RNA editing therapies designed to treat both rare and highly prevalent human diseases. The enterprise utilizes its proprietary Oligonucleotide Promoted Editing of RNA platform—known as OPERA—which enables precise, targeted alterations at the RNA level without introducing permanent, irreversible changes to the underlying genomic DNA. This innovative therapeutic approach allows the company to correct disease-causing mutations, restore normal protein function, and modulate gene expression across multiple therapeutic areas with high precision and minimized off-target safety risks.